Introduction {#S1}
============

The major histocompatibility complex class II (MHC-II) genes encode cell surface α/β heterodimeric glycoproteins that present foreign antigens to antigen specific CD4+T lymphocytes in order to initiate, control, and/or maintain adaptive immune responses [@R1]. There are three MHC-II isotypes HLA-DR, -DQ, and --DP encoded within the MHC-II locus. This process is aided by two other MHC-II associated molecules, HLA-DM and --DO, which are also α/β heterodimers with sequence and structural homology to MHC-II proteins [@R2], [@R3]. Although the levels of mRNA and protein from each of the above genes differ, all are typically coexpressed in a tissue specific manner. MHC-II genes are expressed constitutively in B-lymphocytes, macrophages, dendritic cells, and thymic epithelia and can also be induced in most other cell types following exposure to interferon-γ (reviewed in [@R4]).

The transcription of MHC-II genes is coordinated by a conserved group of transcriptional factors, RFX (regulatory factor X), CREB (cAMP response element binding protein), and NF-Y (nuclear factor-Y), which bind to highly conserved, promoter-proximal sequences termed the X1, X2, and Y boxes, respectively [@R4]--[@R6]. CIITA (class II transactivator), a non-DNA binding transcription factor, is recruited to the DNA bound X and Y box transcription factors and mediates the interaction between co-factors, chromatin remodeling factors, and general transcription machinery [@R5], [@R7], [@R8]. CIITA expression is limiting and is highly regulated [@R9]--[@R11]. In addition to the promoter proximal elements, distal elements contribute to the expression of the genes in this locus [@R12]--[@R14]. The MHC-II locus is punctuated by a series of CCCTC transcription factor (CTCF) binding sites [@R15]. CTCF binding to its target DNA sequences is methylation sensitive [@R16], [@R17], and CTCF has been shown to demarcate and insulate regions of regulatory activity within the genome by functioning as an enhancer blocker [@R18] or by preventing the spread of heterochromatin into active genes [@R19]--[@R21]. CTCF has been proposed to function in part by forming the nexus of long-range chromatin loops. Recently, CTCF was found to be required for the expression of all MHC-II genes [@R15], [@R22]. The binding of CTCF to the insulator site between *HLA-DR* and *HLA-DQ*, termed *XL9*, results in the formation of long-range chromatin loops between *XL9* and the promoter proximal regulatory X-Y box regions of the flanking genes, *HLA-DRB1* and *HLA-DQA1*. This interaction was coincident with gene expression and dependent on CTCF and CIITA binding to their respective sites [@R22]. The depletion of CTCF by RNAi, resulted in the loss of *HLA-DRB1* and *HLA-DQA1* gene expression. These studies predict that disruption of CTCF binding to one of the MHC-II insulator sites may have a significant consequence on MHC-II gene expression.

In 1978, Lazirus et al. established the Laz221 cell line from a patient with acute lymphoblastic leukemia [@R23]. Laz221 cells were similar in phenotype to the ALL cells of the patient and were considered to represent null cells at the time. Later Laz221 cells were determined to be most similar to a pre-B lymphocyte and were thought to arise from these cells [@R24], [@R25]. The cell line Laz388 was established from the same patient by transforming with Epstein-Barr-virus [@R23], [@R26] and represented a normal peripheral B cell. One curious difference between the cells was that whereas Laz388 expressed both HLA-DR and HLA-DQ proteins, Laz221 only expressed the HLA-DR proteins [@R24], [@R25]. Analysis of the cells showed that the HLA-DR genes were expressed in Laz221 but neither HLA-DQA or HLA-DQB was expressed [@R24]. Examination of the *cis*-regulatory elements by transfection of DNA reporter constructs into each of the cell lines and the use of EMSAs suggested that the *HLA-DQB1* gene was regulated differently and that the Laz221 cell line was lacking a critical component [@R24], [@R27]. Because Laz221 expressed HLA-DR molecules at normal levels, this meant that each of the MHC-II specific transcription factors RFX5, RFX-B, RFXAP, and CIITA were present and fully active and that some other aspect of the system was defective. Upon discovery of *XL9* and its role in *HLA-DRB1* and *HLA-DQA1* transcription, we hypothesized that the differential expression of the HLA-DQ locus in Laz221 might involve the use of *XL9*. We found that the region between and including the two insulators *XL9* and *C2* was hypermethylated in Laz221 but not Laz388 cells. DNA methylation resulted in the loss of CTCF binding and long distance interactions between the *XL9* and MHC-II gene promoters. Critically, treatment with 5'-deoxyazacytadine (5-azaC) reverted each of the molecular defects in Laz221 cells, resulting in the reexpression of the HLA-DQ genes. Thus, these data point to DNA methylation of an MHC-II subregion and insulator as a potential mechanism by which cells may attempt to avoid detection by the immune system through the loss of an MHC-II isotype.

Results {#S2}
=======

CTCF does not bind to the MHC insulators that surround the HLA-DQ subregion in Laz221 cells {#S3}
-------------------------------------------------------------------------------------------

Previous analyses demonstrated differential expression of HLA-DR and HLA-DQ surface protein levels between the Laz221 and Laz388 cell lines [@R24], [@R25]. This data is recapitulated in [Figure 1A](#F1){ref-type="fig"}, which shows two distinct expression profiles for these cells. Previous work also showed that *HLA-DQB* mRNA was not expressed in Laz221 [@R24]. Confirmation of that result showed that compared to Laz388, Laz221 cells had extremely low levels of *HLA-DQB1* mRNA. Additionally in Laz221 cells *HLA-DQA1* mRNA levels were very low, suggesting that the cause of expression may be related to the HLA-DQ locus. Similar levels of *HLA-DRB1* transcripts were observed between the cell lines ([Figure 1B](#F1){ref-type="fig"}). Southern hybridization experiments showed that *HLA-DRB1* and *HLA-DQB1* were similar in both cell lines, indicating no major deletion in the genes [@R24]. Since the previous analyses of these cell lines, we now know that the RFX complex (RFX5, RFX-B, and RFXAP) and CIITA are specific to and required for the expression of all MHC-II genes [@R4]. The finding that HLA-DR is expressed on the surface and that *HLA-DRB1* mRNA is present in Laz221 cells argues that the RFX subunits, CIITA, and other necessary transcription factors for MHC-II transcription are fully functional in Laz221 cells.

Our recent discovery that *HLA-DQA1* utilized the *XL9* insulator as a distal regulator of HLA-DQA1 expression [@R22], led us to examine if *XL9* was mutated in Laz221 cells. However, DNA sequencing of genomic clones isolated from Laz221 and Laz388 showed identical sequences (data not shown). We also tested whether CTCF, the insulator factor at *XL9* that is responsible for its MHC-II regulatory activity, was normally expressed Laz221 cells. Western blotting of both Laz388 and Laz221 revealed that the overall levels of CTCF are similar with Laz221 expressing slightly more CTCF than Laz388 cells ([Figure 2A](#F2){ref-type="fig"}).

In addition to *XL9,* another CTCF binding insulator termed *C2*, was recently identified that lies between *HLA-DQB1* and the pseudogene *HLA-DQA2* ([Figure 2B](#F2){ref-type="fig"}, Majumder and Boss, unpublished results). *C2* interacts with *XL9,* and like *XL9* forms long-distance interactions with the proximal promoters of *HLA-DQA1* and *HLA-DQB1* (Majumder and Boss, unpublished results). Thus, to determine if CTCF binding to Laz221 was similar to that in Laz388, chromatin immunoprecipitation assays were performed at *XL9* and *C2* ([Figure 2B](#F2){ref-type="fig"}). Whereas CTCF bound to *XL9* and *C2* in Laz388 cells, it did not bind to these sites in Laz221 cells. The binding of CTCF was specific as shown by the non-specific DNA and antibody controls presented ([Figure 2B](#F2){ref-type="fig"}). This suggested that a potential cause for the lack of HLA-DQ expression could be do to the inability to bind CTCF at *XL9* and *C2*.

XL9 and the HLA-DQ region are hypermethylated in Laz221 cells {#S4}
-------------------------------------------------------------

DNA methylation is a heritable mark that can result in reducing the accessibility of DNA to transcription factors by controlling the local chromatin structure. DNA methylation is also known to prevent CTCF binding to its target sequences [@R16], [@R17], [@R31]; suggesting a mechanism by which CTCF binding may be abrogated in Laz221 cells. To determine if DNA methylation may play a role in the differential expression of the *HLA-DQ* genes, methyl-DNA immune precipitation assays (MeDIP) were conducted across the *HLA-DQ* subregion [@R29]. In MeDIP, DNA is fragmented by sonication to produce fragments of 600--1,000 bp in length. A methylcytosine specific antibody is used to immunoprecipitate the DNA prior to analysis by real-time PCR. The MeDIP technique circumvents the sequence bias that is present in the methylation sensitive restriction digestion technologies and can be rapidly applied across a region. A series of amplicons from just upstream of *XL9* to downstream of *C2* was designed and used to assess the locus. The results showed that the sequences surrounding *XL9* were highly enriched for cytosine methylation in Laz221 cells but showed no methylation in Laz388 ([Figure 3](#F3){ref-type="fig"}). Additionally, each of the promoter regions surrounding the *HLA-DQA1* and *HLA-DQB1* genes were also methylated in Laz221 cells but not in Laz388. Lastly, the *C2* insulator was also hypermethylated in Laz221 cells compared to Laz388. In contrast, the *HLA-DRB1* proximal promoter region and that of a CpG island in the β-actin gene showed no enrichment for methylcytosine containing DNA. Intriguingly, the sequences represented by amplicons C2a and C2b, which lie outside of the *XL9-C2* defined HLA-DQ region showed no cytosine DNA methylation, suggesting that C2 was the boundary of this epigenetic mark. Sequences XL9a and XL9b, which represent random regions also outside of the XL9-C2 domain, exhibited DNA methylation irrespective of the cell line, suggesting that methylation of these sequences is normally associated with this intergenic region. While the number of methylated cytosines correlates with signal strength in the MeDIP assay, the data collected were not simply due to the number of potential CpGs within a region as *XL9* has fewer CpG sites within the 500 bp surrounding DNA than *HLA-DQA1* or HLA-DQB1 ([Table 1](#T1){ref-type="table"}).

In addition to DNA methylation chromatin accessibility is modulated through a variety of histone modifications that serve to recruit heterochromatin-modulating factors. One such factor is heterochromatin protein-1 (HP-1), which recognizes chromatin that contains histone H3K9me3 posttranslational modifications [@R32]. To determine if the regions bearing DNA methylation carried heterochromatin modifications, ChIP assays were carried out for HP-1 and H3K9me3 ([Figure 4](#F4){ref-type="fig"}). The results showed that the repressive histone modification and HP-1 were present at *XL9* chromatin but not at the proximal promoters in Laz221 cells. Neither the mark nor HP-1 was found at these sites in Laz388 cells. Together, these data demonstrate that the *HLA-DQ* subregion is hypermethylated in Laz221 cells and that the *XL9* insulator region is packaged in a repressive chromatin structure that would be predicted to silence its function.

The *HLA-DQ* proximal promoter regions do not bind RFX and CIITA {#S5}
----------------------------------------------------------------

The DNA methylation patterns over the proximal promoter regions of the *HLA-DQA1* and *HLA-DQB1* genes suggest that RFX and CIITA may not be able to bind to their respective sequences. To test this hypothesis, the in vivo occupancies of RFX5 and CIITA to the *HLA-DRB1* and *HLA-DQA1* in Laz221 and Laz388 cells were determined by ChIP. As expected RFX5 and CIITA bound to the promoter proximal regions of *HLA-DRB1* in both cell lines and to *HLA-DQA1* and *HLA-DRB1* in Laz388. However, RFX5 and CIITA did not bind to the promoter proximal region of HLA-DQA1 or HLA-DQB1 ([Figure 5](#F5){ref-type="fig"}). This suggests that DNA methylation may prevent the assembly of the active proximal promoter regulatory regions and actions of *XL9* and *C2*.

Inhibition of DNA methyltransferase reverses the differential expression of HLA-DQ genes in Laz221 cells {#S6}
--------------------------------------------------------------------------------------------------------

To determine if DNA methylation was responsible for the Laz221 phenotype, Laz221 cells were treated for two days with 5azaC, an inhibitor of the maintenance DNA methyltransferase DMNT1 [@R33]--[@R35]. Total RNA was isolated and analyzed for the expression of *HLA-DRB1, HLA-DQA1*, and *HLA-DQB1* mRNA levels ([Figure 6A](#F6){ref-type="fig"}). While 5azaC treatment increased the levels of *HLA-DRB1* by 3-4-fold (data not shown); the levels of *HLA-DQA1* were increased by 40-fold and levels of *HLA-DQB1* were increased by 7.5 fold over the untreated cultures. Moreover, 5azaC treatment also resulted in the ability of RFX5, CIITA, and CTCF to bind their target sites in Laz221 cells ([Figure 6B](#F6){ref-type="fig"}).

*XL9* functions by interacting directly with the proximal promoter regions of the *HLA-DRB1* and *HLA-DQA1* genes [@R22]. *C2* was found to interact with *HLA-DQA1* and *HLA-DQB1* (Majumder and Boss unpublished). Disruption of these interactions by depleting CTCF results in a loss of expression from these promoters [@R22]. Thus, it was of interest to determine if the DNA methylation played a role in these interactions. Interactions between distal elements can be observed using the chromatin conformation capture assay, termed 3C [@R22], [@R30]. The formation of a 3C product provides a measure of the spatial proximity of the elements in question compared to a randomly selected element. Here, the ability of *XL9* and *C2* to interact with the promoter proximal restriction fragments of *HLA-DRB1* and *HLA-DQA1* was compared to random sequences located within the locus. Previous analyses have characterized these elements and the controls required to demonstrate that the system was operational [@R22] (Majumder and Boss, unpublished). In Laz388, 3C products were formed between *XL9* and *HLA-DRB1* and *HLA-DQA1*, but not with the control fragments P12 and P19 ([Figure 7B](#F7){ref-type="fig"}). In Laz221, 3C products were not observed between *XL9* and either promoter proximal restriction fragment. Similarly, *C2* interacted with *HLA-DQA1* and *HLA-DQB1* in Laz388 but not in Laz221 ([Figure 7C](#F7){ref-type="fig"}). These results indicate that the insulator regions were not active in modulating MHC-II activity in Laz221 cells. The inability to form 3C products in Laz221 was not due to restriction site accessibility as the conditions used still allowed enzyme access to the sites of the isolated chromatin (Supplemental Figure 1). Treatment of Laz221 cells with 5azaC resulted in the formation of the *XL9---HLA-DQA1, C2---HLA-DQA1,* and *C2---HLA-DQB1* 3C interactions at comparable frequencies to those observed in Laz388. No interactions were observed with the control fragments following 5azaC treatment. Thus, DNA methylation in this system also blocks *XL9* and *C2* function.

Discussion {#S7}
==========

The pre B cell leukemia derived cell line Laz221 was isolated from the patient who was diagnosed with acute lymphocytic leukemia in 1978 [@R23]. A normal B cell line Laz388 was also established from the same patient [@R26]. Nearly, a decade later it was found that these cells differentially expressed MHC-II genes [@R24], [@R25]. At that time, the differential *HLA-DQ* expression was postulated to be due to a deficiency in Laz221 that was specific to the expression of the *HLA-DQB* gene [@R24], [@R27]. With the current understanding that all MHC-II isotypes are coordinately regulated by a common set of factors [@R4], [@R10] and the recent identification of insulator elements that contribute to the expression of the locus, we sought to reinvestigate this cell line and its autologous partner Laz388 to determine the molecular basis of the differential expression of the *HLA-DQ* genes. The results showed that the *HLA-DQ* subregion of the MHC was hypermethylated in Laz221 compared to Laz388 cells. DNA hypermethylation disabled three separate mechanistic events necessary for the expression of an MHC-II gene. Importantly, inhibition of DNA hypermethylation within the *HLA-DQ* subregion restored *HLA-DQ* gene expression and each of the biochemical pathways associated with HLA-DQ gene regulation.

The first of these events was that DNA methylation of the *HLA-DQA1* and *HLA-DQB1* proximal promoter X-Y box sequences prevented the assembly of the RFX and CIITA enhanceosome complex that is required for MHC-II gene expression [@R7], [@R10]. Without the binding of these factors to the proximal promoter regions, the transcription of these genes could not occur. Thus, in a gene specific manner, the DNA methylation of the proximal promoters created a situation that mimicked the phenotype of an RFX-subunit-deficient bare lymphocyte patient's B cells [@R36], [@R37] where the critical factors failed to assemble [@R38]. The observations that RFX and CIITA were bound at *HLA-DRB1* in Laz221 cells, and that 5azaC reverted the binding of these factors to *HLA-DQA1* provides evidence that the chromatin samples and assay system used in these ChIP experiments are sufficiently controlled.

Second, DNA methylation of *XL9* and *C2* resulted in chromatin that could not bind CTCF. This effectively removed CTCF from being able to participate in the activation of the neighboring MHC-II genes. A surprise was that in addition to *XL9* and *C2* being hypermethylated, we found that the *XL9* region contained high levels of the repressive histone modification H3K9me3 and was associated with HP-1, the heterochromatin protein that recognizes this mark [@R39], [@R40]. This suggests the possibility that this region is packaged in a heterochromatic state and that the histone modification is playing a role in the silencing of the region. The heterochromatin mark did not spread to the *HLA-DQ* gene promoter regions, suggesting that it was highly localized. Third, the loss of both CIITA and CTCF binding to their target sites had the net effect of eliminating the ability of these sites to interact with each other. Thus, the long-distance chromatin loops that form between the CTCF sites and the *HLA-DQ* genes did not occur. In addition to *XL9* and *C2*, the MHC-II region has 8 other CTCF sites in the locus [@R15]. These CTCF sites interact with each other, as well as the neighboring MHC-II gene promoters. Although large in scale (\~150--200 kb), the frequency of interactions is dependent on the distance between the sites. CTCF binding is required for these sites to interact with each other and CIITA is required for additional interactions between the CTCF sites and MHC-II gene promoter regions [@R15]. Thus, the DNA methylation and heterochromatin events at the two insulators that border the HLA-DQ subregion, disrupt the normal architecture of the locus.

The loss of CTCF binding to *XL9* raises the issue of how *HLA-DRB1* can be expressed as its closest CTCF site is silenced. In addition to *XL9, HLA-DRB1* interacts with the CTCF site that is upstream of the *HLA-DRA* gene, termed *C1* [@R15]. Thus, it has a choice of which site it can use. The data presented here suggests that the loss of one available CTCF site does not prevent expression of an MHC-II gene if another site can be used. Thus, the system has redundancies built in. Intriguingly, in Raji cells, *HLA-DQA1* interacts with only *XL9* and *C2* [@R15], for which both of these sites are inactive in Laz221.

Transcriptional insulators are often complex elements that in addition to having the ability to block an enhancer from activating a downstream target gene, they can also prevent the encroachment of heterochromatin into a region [@R41]. This latter activity is attributed to barrier or boundary function of the elements. More recently the activities associated with the β-globin HS4 insulator, which exhibited all of these activities, have been dissected and individual functions, enhancer blocking vs boundary function, were found to be the result of separate definable elements [@R42]. This raises the question as to whether the CTCF binding sites within the MHC-II locus have multiple activities. *XL9* mediates strong enhancer blocking activity [@R12]; however, barrier activity was not assessed for *XL9* or any of the other MHC-II CTCF elements. In the results presented here, the differential DNA hypermethylation did not appear to spread outside of the *HLA-DQ* region. Because CTCF cannot bind to its sites, it is reasonable to postulate that it does not contribute to such an activity. This assessment is consistent with the fact that the zinc finger protein VEZF1 was found to be responsible for preventing the spread of heterochromatin in the HS4 insulator [@R42].

DNA methylation of MHC-II genes has been observed previously and correlated with silencing of the locus [@R43]--[@R45]. In these studies, the HLA-DR region was methylated as determined by Southern blots and methylation sensitive restriction enzymes, and *HLA-DQ* genes were not assessed. In other studies, differential HLA-DR and --DQ expression was observed, but the molecular basis was not established [@R25], [@R46]--[@R48]. Thus, there is a long history of methylation as a mechanism to control MHC-II expression. Because MHC-II gene products are typically co-expressed, this raises the question of how both alleles received the same epigenetic mark to silence the *HLA-DQ* subregion. We pose that there are two possibilities. The first is that the Laz221 leukemic line may represent a developmental snap shot of B cell development. In such a scenario, the *HLA-DQ* region would be normally silenced and activated at a later developmental cell stage. Several reports support this notion. HLA-DQ expression was reported to lag behind HLA-DR and HLA-DP during early fetal development [@R46]. Additionally hematopoegenic progenitors were found to express HLA-DR and HLA-DP but not HLA-DQ [@R48]. Lastly, in a similar vein, it is possible that the entire locus is controlled by DNA methylation events. In embryonic and pluripotent stem cells, *HLA-DRA* was not expressed or inducible by IFNγ, unless the cells were pretreated with 5azaC [@R49]. Bisulfite sequencing showed that the *HLA-DRA* locus was hypermethylated in these cells.

A second possibility is that a strong selection event led to the silencing of both *HLA-DQ* alleles and that DNA methylation was the successful strategy to silence the loci. In diffuse large B cell lymphoma (DLBCL), MHC-II expression is often lost through a variety of mechanisms some of which include the reduction of CIITA expression but others remain unknown [@R50]--[@R53]. In these cancers, the loss of MHC-II expression is associated with a poorer prognosis than those lymphomas expressing MHC-II [@R51]. Fewer tumor infiltrating CD8 T cells were associated with MHC-II negative DLBCLs than MHC-II positive, suggesting a connection between MHC-II positive cells and tumor surveillance mechanisms. The DNA methylation events found associated with Laz221 cells represent one mechanism by which MHC-II genes and a particular isotype can be silenced; thus, it would not be surprising if other lymphomas/leukemias were ultimately identified that displayed MHC-II silencing events that occurred through a DNA methylation and/or the loss of an MHC-II specific insulator function.

Materials and Methods {#S8}
=====================

Cell culture {#S9}
------------

The Laz221 and Laz388 cell lines [@R23], [@R26] originally derived from the peripheral blood of a patient with acute lymphocytic leukemia. These two cell lines were obtained from Dr. G. Nepom (Benaroya Institute, WA) and were grown in RPMI-HEPES supplemented with 10% fetal bovine serum (Hyclone, Inc., Logan, UT), 2 mM L-glutamine, penicillin /streptomycin 50 U/ml and 1mM Sodium pyruvate. Laz221 cells were grown in the absence or presence of 5 µM 5'-deoxyazacytadine (5azaC) (Sigma-Aldrich, Cat\#A2385). 5azaC was added at 8 hour intervals to the growth media for 2 days.

Flow cytometry {#S10}
--------------

Cells were harvested, washed twice with cold PBS, and incubated with phycoerythrin (PE)-conjugated anti-human HLA-DR antibody or unconjugated anti-human HLA-DQ antibody (BD bioscience Pharmingen, San Diego, CA) followed by staining with a PE-conjugated anti--mouse IgG secondary antibody (Southern Biotech). A FACScalibur (BD Biosciences) flow cytometer was used to analyze the expression level of human MHC-II surface expression. MHC-II positive cells were visualized using the FL2 channel. Control stained samples were processed in parallel using only the secondary antibodies indicated in the figures.

Quantitative RT-PCR {#S11}
-------------------

Total RNA was isolated from Laz388 and Laz221 cells using the RNeasy RNA isolation kit (QIAGEN, Valencia, CA) according to the company's protocol. cDNA synthesis was performed using Superscript II reverse transcriptase (Invitrogen, Inc., Carlsbad, CA) with 2 µg of total RNA in a volume of 20 µl in PCR II buffer containing 5 mM MgCl~2~ (Applied Biosystems, Foster City, CA). After reverse transcription, sample volumes were increased to 200 µl with TE buffer and 3 µl of the cDNA was used for quantitative PCR assays. *GAPDH* primers were used in each of the experiments to normalize the data between samples. PCR primers are listed in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}. The data presented represent the average of three independent experiments and are plotted with their standard deviation. The student's T test was used to determine statistical significance.

Chromatin immunoprecipitation (ChIP) assay {#S12}
------------------------------------------

ChIP assays were performed as described previously [@R8], [@R12], [@R14], [@R22]. For immunoprecipitations, 5--10 µg of anti-CTCF (Upstate, Cat no. 06-917), anti-RFX5 [@R28], anti-CIITA [@R8], or anti-T-cell receptor (non-specific control) antibodies were used. Protein A beads (60 µl) were used to isolate the chromatin-antibody bound complexes. After extensive washing, the immunoprecipitated chromatin was eluted in 1% SDS and incubated overnight at 65°C to reverse the crosslinks. The DNA was purified and used as a template in real-time PCR analyses. Immunoprecipitated DNA samples were quantitated by real-time PCR using a 5-point genomic DNA standard curve and an I-cycler (Biorad Laboratories, Inc.) as previously described [@R22]. SYBR-Green incorporation quantitative PCR reactions contained 5% DMSO, 1 X SYBRgreen (Bio Whittaker Molecular Applications), 0.04% gelatin, 0.3% Tween 20, 50 mM KCl, and 20 mM Tris \[pH 8.3\], 3 mM MgCl~2~, 0.2 mM dNTP, and 100 nM of each primer. Primer sequences are listed in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}. All ChIP experiments were performed at least three times from independent preparations of chromatin. The data were averaged and plotted as a percentage of input chromatin with standard error bars as indicated.

Quantitative methylated DNA immunoprecipitation (MeDIP) assay {#S13}
-------------------------------------------------------------

MeDIP assays were performed as described by Weber et al. [@R29] with the following modifications. Genomic DNAs were purified from Laz388 and Laz221 cells using DNAzol genomic DNA isolation reagent as described by the manufacturer (Molecular Research Center, Inc., Cat no. DN-127). Genomic DNAs were sonicated in TE buffer to produce random fragments of about 600 bp. 4 µg of fragmented DNA for each experimental sample was denatured and incubated for 2 hr with 5 µg of anti-5-methylcytidine antibodies (Eurogenetec, Inc.; Cat no. BI-MECY-0100) in a final volume of 500 µl of IP buffer (10 mM sodium phosphate (pH 7.0), 140 mM NaCl, 0.05% Triton X-100). Thirty µl of Dynabeads (M-280 sheep antibody to mouse IgG; Dynal Biotech, Inc.) were used to isolate the 5-methycytidine bound DNA complexes. After extensive washing and treating with proteinase K, the immunoprecipitated DNA was extracted with phenol-chloroform, and recovered by ethanol precipitation. To quantitate the samples, real-time PCR was carried out with input and the immunoprecipitated DNAs as described in the above section for ChIP assays.

Quantitative chromosome conformation capture (3C) assay {#S14}
-------------------------------------------------------

3C assays [@R30] were performed with modifications described previously [@R22], [@R30]. Here, 1×10^7^ cells were isolated, cross-linked with formaldehyde to a final concentration of 1% for 10 minutes at room temperature and glycine was added to 125 mM to stop the crosslinking reaction. Nuclei were purified and digested overnight with *Eco*RI at 37°C. Following heat inactivation of the enzyme, the samples were diluted \~40:1 and then ligated with T4 DNA ligase. The DNA was purified and then used as a substrate for real-time PCR using the primers described in [@R22] and shown in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}. All restriction sites assessed by 3C were equally accessible to restriction enzyme digestion as determined by PCR amplification across the sites following digestion. Standard curve templates for the 3C products were generated in vitro by restriction enzyme cleaving and religating the bacterial artificial chromosome (BAC) RP11-257P24 (purchased from Children's Hospital Oakland Research Institute), which encodes the *HLA-DRB1* and *HLA-DQA1* subregion and includes *XL9* and C2. All primer combinations are listed in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}), and were tested previously [@R22] had a greater than 90% PCR efficiency, and produce a single amplicon on cleaved/religated BAC DNA. Data are presented as crosslinked frequency and represent an average derived from three independent biological replicates. Standard error is provided for the dataset. Student's T tests were used to determine if observed differences were significant.
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![Laz221 cells express HLA-DR but not HLA-DQ gene products\
A) Surface MHC-II expression patterns were assessed using flow cytometry with isotype control, anti-HLA-DQ, and anti-HLA-DR antibodies. This figure represents one of the two independent experiments. B) mRNA levels for *HLA-DRB1, -DQA1,* and *-DQB1* genes were determined by the real-time RT-PCR using RNAs prepared from the Laz388 and Laz221 cells. These data represent an average derived from three biological replicates plotted with respect to the expression in Laz388. Standard error is shown for Laz221 cells.](nihms233091f1){#F1}

![CTCF does not bind to HLA-DQ flanking insulator elements *XL9* and *C2*\
A) Western blot of cell lysates from Laz388 and Laz221 stained with anti-CTCF and anti-β-actin antibodies demonstrated near equal levels of CTCF in both cell lines. B) Quantitative real-time ChIP assays were performed using chromatin prepared from the Laz388 and Laz221 cells with anti-CTCF and non-specific control antibodies to determine the in vivo occupancy of CTCF at *XL9, C2*, and promoter regions of *HLA-DRB1, -DQA1,* and --*DQB1* genes. The schematic shows the relative positions of the amplicons used to assess CTCF binding across this region. Strong CTCF binding was detected at the *XL9* and *C2* elements in Laz388 cells while no significant binding was detected at these sites in Laz221 cells. These results are represented of the compiled data from three biological replicates and are presented with standard error as the percentage of input chromatin used for the ChIP assay.](nihms233091f2){#F2}

![The HLA-DQ subregion is hypermethylated in Laz221 cells but not in Laz388\
A) Schematic diagram shows the *HLA-DRB1- C2* region of MHC-II locus and position of primers used for the real time PCR following immunoprecipitation. B) Denatured sonicated genomic DNAs from Laz388 and Laz221 were incubated with and without anti-5-methyl-cytosine (α-5mC) antiserum, and the methylated DNAs were collected by immunoprecipitation. The relative enrichment in the bound DNA over input fractions was determined by quantitative real-time PCR for the regions shown in A. These data represent the average with standard error derived from three independent cell cultures.](nihms233091f3){#F3}

![XL9 chromatin is marked by histone H3K9me3 modifications and bound by HP-1\
Quantitative real-time ChIP assays were conducted using control, anti-histone H3K9me3, and anti-HP-1 antibodies on chromatin prepared from Laz388 and Laz221 cells with amplicons representing *XL9* and the proximal promoter regions of *HLA-DRB1* and *HLA-DQA1* genes. These data represent an average with standard error derived from three independent chromatin preparations. The data are plotted with respect to the percent of input chromatin for that region.](nihms233091f4){#F4}

![RFX and CIITA do not bind to the *HLA-DQA1* and *HLA-DQB1* promoter proximal WXY box regions\
Quantitative ChIP assays were performed as in [Figures 2](#F2){ref-type="fig"} and [4](#F4){ref-type="fig"} with the indicated antibodies to assess the in vivo occupancy of the RFX5 and CIITA at the promoter proximal regions of *HLA-DRB1* and *HLA-DQ* genes and the *XL9* and *C2* elements. No significant binding of RFX5 and CIITA was observed at the HLA-DQ promoter proximal region in Laz221 cells. In contrast to this, high levels of RFX5 and CIITA were detected at the same region in Laz388 cells. High levels of RFX5 and CIITA were observed on *HLA-DRB1* promoter where no significant difference was found in both cell lines. *XL9* and *C2* do not bind RFX or CIITA. These data were derived from three independent chromatin preparations.](nihms233091f5){#F5}

![Inhibition of DNA methylation derepresses *HLA-DQ* gene expression\
Laz221 cells were treated with 5azaC for two days as described in the materials and methods. Total RNA and chromatin were purified from the cells after two days and compared to control, untreated Laz221 cells. A) mRNA levels for *HLA-DQA1* and *-DQB1* genes were determined by the real-time RT-PCR. Results are shown with respect to the levels of *GAPDH* mRNA, which did not change appreciably (data not shown). B) Quantitative real-time ChIP assays were performed as above with indicated antibodies to assess the in vivo occupancies of RFX, CIITA, and CTCF at *HLA-DQA1, -DQB1, -DRB1, XL9 and C2*. The average of three independent experiments is presented.](nihms233091f6){#F6}

![Interactions between the *XL9* and *C2* insulator elements with H*LA-DQ* genes are restored in Laz221 cells following inhibition of DNA methylation\
A) Schematic restriction map showing the relevant portions of the *HLA-DQ* locus and *HLA-DRB1* gene. Vertical bars show the positions of the *Eco*RI sites in the region. The positions of the PCR primers representing the restriction fragment assessed in the 3C assays are depicted by arrowheads and designated by the name below. The position of the insulators *XL9* and *C2* are represented by ovals. For these 3C assays chromatin was prepared from Laz388, Laz221, and Laz221 cells treated with 5azaC. B) 3C assay in which *XL9* served as the anchor region to test interactions between the *XL9* restriction fragment and the indicated restriction fragment containing the *HLA-DRB1* or -DQA1 promoter. C) 3C assays in which *C2* served as the anchor primer to test interactions between the *C2* restriction fragment and other restriction fragments containing either the *HLA-DQA1* or *-DQB*1 promoters. The data from three independent 3C chromatin preparations was averaged and plotted with respect to the relative amount of 3C product. Control restriction fragments are indicated as the P12, P19, CL4 and CL5 primer-positions.](nihms233091f7){#F7}

###### 

CpG dinucleotides per locus

  Locus                                                                  CpGs[\*](#TFN1){ref-type="table-fn"}
  ---------------------------------------------------------------------- --------------------------------------
  *HLA-DRB1* proximal promoter region                                    6
  XL9a (4000 bp from the core *XL9*)[\*\*](#TFN2){ref-type="table-fn"}   14
  XL9b (2000 bp from the core *XL9*)                                     4
  *XL9*                                                                  3
  *HLA-DQA1* proximal promoter region                                    14
  *HLA-DQB1* proximal promoter region                                    70
  *C2*                                                                   8
  C2b (2000 bp from the core XL9)                                        4
  C2a (4000 bp from the core XL9)                                        9
  *b-Actin* promoter region                                              110

CpGs in the 500 bp that encompasses the locus

See Schematic for relative location
